Watson's New Oxytrol Strategy: Specialty Care Market, Fewer Reps
This article was originally published in The Pink Sheet Daily
Executive Summary
The company is "not equipped to compete" with Pfizer (Detrol) and J&J (Ditropan XL) in the primary care market for overactive bladder therapies, CEO Chao says. Watson is terminating its agreement with contract sales organization Ventiv, which supplied 380 primary care reps for Oxytrol.